Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jay N Cohn

Showing results (81-90 of 171) with videos related to

Pageof 18
Sort By:
Journal of the American College of Cardiology|August 28, 2007
Beneficial effects of valsartan in asymptomatic individuals with vascular or cardiac abnormalities: the DETECTIV Pilot StudyDaniel A Duprez, Natalia D Florea, Kathryn Jones, et al.
Journal of the National Medical Association|October 24, 2002
The African-American Heart Failure Trial: background, rationale and significanceAnne L Taylor, Jay N Cohn, Manuel Worcel, et al.
Journal of Cardiac Failure|October 30, 2003
Ventricular remodeling in heart failure: a credible surrogate endpointMarvin A Konstam, James E Udelson, Inder S Anand, et al.
Journal of Human Hypertension|November 30, 2017
Effect of nebivolol or atenolol vs. placebo on cardiovascular health in subjects with borderline blood pressure: the EVIDENCE studyDaniel A Duprez, Natalia Florea, Sue Duval, et al.
Circulation|July 1, 2004
Surrogate markers for cardiovascular disease: functional markersJay N Cohn, Arshed A Quyyumi, Norman K Hollenberg, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|November 3, 2009
Definition and classification of hypertension: an updateThomas D Giles, Barry J Materson, Jay N Cohn, et al.
Circulation. Heart Failure|July 15, 2016
Heart Failure With Improved Ejection Fraction: Clinical Characteristics, Correlates of Recovery, and Survival: Results From the Valsartan Heart Failure TrialViorel G Florea, Thomas S Rector, Inder S Anand, et al.
Hypertension (Dallas, Tex. : 1979)|March 29, 2017
Office Blood Pressure and Cardiovascular Disease: Pathophysiologic Implications for Diagnosis and TreatmentJay N Cohn, Daniel A Duprez, Lynn Hoke, et al.
Clinical Pharmacokinetics|September 15, 2007
Lack of bioequivalence between different formulations of isosorbide dinitrate and hydralazine and the fixed-dose combination of isosorbide dinitrate/hydralazine: the V-HeFT paradoxS William Tam, Michael L Sabolinski, Manuel Worcel, et al.
The New England Journal of Medicine|August 1, 1991
Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure, Salim Yusuf, Bertram Pitt, et al.
Pageof 18

Showing results (81-90 of 171) with videos related to

Sort By:
Pageof 18
Journal of the American College of Cardiology|August 28, 2007
Beneficial effects of valsartan in asymptomatic individuals with vascular or cardiac abnormalities: the DETECTIV Pilot StudyDaniel A Duprez, Natalia D Florea, Kathryn Jones, et al.
Journal of the National Medical Association|October 24, 2002
The African-American Heart Failure Trial: background, rationale and significanceAnne L Taylor, Jay N Cohn, Manuel Worcel, et al.
Journal of Cardiac Failure|October 30, 2003
Ventricular remodeling in heart failure: a credible surrogate endpointMarvin A Konstam, James E Udelson, Inder S Anand, et al.
Journal of Human Hypertension|November 30, 2017
Effect of nebivolol or atenolol vs. placebo on cardiovascular health in subjects with borderline blood pressure: the EVIDENCE studyDaniel A Duprez, Natalia Florea, Sue Duval, et al.
Circulation|July 1, 2004
Surrogate markers for cardiovascular disease: functional markersJay N Cohn, Arshed A Quyyumi, Norman K Hollenberg, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|November 3, 2009
Definition and classification of hypertension: an updateThomas D Giles, Barry J Materson, Jay N Cohn, et al.
Circulation. Heart Failure|July 15, 2016
Heart Failure With Improved Ejection Fraction: Clinical Characteristics, Correlates of Recovery, and Survival: Results From the Valsartan Heart Failure TrialViorel G Florea, Thomas S Rector, Inder S Anand, et al.
Hypertension (Dallas, Tex. : 1979)|March 29, 2017
Office Blood Pressure and Cardiovascular Disease: Pathophysiologic Implications for Diagnosis and TreatmentJay N Cohn, Daniel A Duprez, Lynn Hoke, et al.
Clinical Pharmacokinetics|September 15, 2007
Lack of bioequivalence between different formulations of isosorbide dinitrate and hydralazine and the fixed-dose combination of isosorbide dinitrate/hydralazine: the V-HeFT paradoxS William Tam, Michael L Sabolinski, Manuel Worcel, et al.
The New England Journal of Medicine|August 1, 1991
Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure, Salim Yusuf, Bertram Pitt, et al.
Pageof 18